Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C - An Observational Study in Israel (CITRINE STUDY)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CITRINE
- Sponsors AbbVie
- 23 Feb 2018 Planned End Date changed from 17 Jun 2018 to 7 Oct 2018.
- 23 Feb 2018 Planned primary completion date changed from 17 Jun 2018 to 7 Oct 2018.
- 23 Feb 2018 Status changed from recruiting to active, no longer recruiting.